Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

57.55 -0.46 (-0.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about! 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Expert Ratings for Biomarin Pharmaceutical
Via Benzinga
Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate
Via Benzinga
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath
And shares of its developer are on a warpath this week. 
Via Investor's Business Daily
Expert Ratings for Biomarin Pharmaceutical
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings: 
Via Benzinga
Why BioMarin Pharmaceuticals Fell 6.9% on Thursday
Investors were expecting better top-line numbers from the company's earnings report. 
Via The Motley Fool
Expert Ratings for Biomarin Pharmaceutical
Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter: 
Via Benzinga
Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are trading higher by 6.97% to $97.54 Wednesday morning after the company announced advancements in the FDA review of ROCTAVIAN for adults with severe... 
Via Benzinga
$1.4 Million Bet On This Real Estate Stock? 3 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
10 Analysts Have This to Say About Biomarin Pharmaceutical
Over the past 3 months, 10 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ:BMRN) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Mastercard To $428? Plus This Analyst Slashes PT On Intel
Barclays cut the price target on Mastercard Incorporated (NYSE: MA) from $430 to $428. Barclays analyst Ramsey El-Assal maintained an Overweight rating on the stock. Mastercard shares fell 0.6% to... 
Via Benzinga
Biomarin Pharmaceutical: Q3 Earnings Insights
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:03 PM. Here's what investors need to know about the announcement. 
Via Benzinga
One Rejected BioMarin's Hemophilia Gene Therapy Goes Under FDA Review
Via Benzinga
BioMarin Lays Off 4% Of Its Workforce To 'Simplify' The Company
Via Benzinga
Expert Ratings for Biomarin Pharmaceutical
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
Recap: Biomarin Pharmaceutical Q3 Earnings
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings
Via Benzinga
Analyst Ratings for Biomarin Pharmaceutical
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings: 
Via Benzinga
BioMarin Says One Participant Diagnosed With Leukemia In Late-Stage Hemophilia Gene Therapy Trial
Via Benzinga
Neurocrine Leads 5 Stocks To Watch In Sickly Market
Neurocrine Biosciences leads five medical stocks showing resilience. 
Via Investor's Business Daily
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
BioMarin Receives European Commission's Conditional Marketing Authorization For Gene Therapy Candidate
The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ: BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the... 
Via Benzinga
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart
  If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Undervalued Biotech Stocks to Buy Before They Boom
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. 
Via InvestorPlace
Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them
Four pharmaceutical stocks, including three biotech movers, are making big moves. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
Upgrades 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.